New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Researchers from the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, ...

COVID, flu and RSV levels have already hit their peaks. (Pollen levels and springtime allergies are a whole different story.) ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute ...

Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...

the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can ...

Seasonal flu showed a 'remarkable' bounce back to pre-pandemic levels once ... Oct. 28, 2024 — Doctors detail what we learned after the first season following the approval of RSV vaccines.

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...